A B S T R A C T
Background: Vascular smooth muscle cells (VSMCs) exhibit phenotypic plasticity, promoting vascular calcification and increasing cardiovascular risk. Changes in VSMC intracellular calcium ([Ca 2þ ] i ) are a major determinant of plasticity, but little is known about changes in [Ca 2þ ] i in chronic kidney disease (CKD). We have previously demonstrated such plasticity in aortas from our rat model of CKD and therefore sought to examine changes in [Ca 2þ ] i during CKD progression. Materials and Methods: We examined freshly isolated VSMCs from aortas of normal rats, Cy/þ rats (CKD) with early and advanced CKD, and advanced CKD rats treated without and with 3% calcium gluconate (CKD þ Ca 2þ ) to lower parathyroid hormone (PTH) levels. [Ca 2þ ] i was measured with fura-2. Results: Cy/þ rats developed progressive CKD, as assessed by plasma levels of blood urea nitrogen, calcium, phosphorus, parathyroid hormone and fibroblast growth factor 23. VSMCs isolated from rats with CKD demonstrated biphasic alterations in resting [Ca 2þ ] i : VSMCs from rats with early CKD exhibited reduced resting [Ca 2þ ] i , while VSMCs from rats with advanced CKD exhibited elevated resting [Ca 2þ ] i . Caffeine-induced sarcoplasmic reticulum (SR) Ca 2þ store release was modestly increased in early CKD and was more drastically increased in advanced CKD. The advanced CKD elevation in SR Ca 2þ store release was associated with a significant increase in the activity of the sarco-endoplasmic reticulum Ca 2þ ATPase (SERCA); however, SERCA2a protein expression was decreased in advanced CKD. Following SR Ca 2þ store release, recovery of [Ca 2þ ] i in the presence of caffeine and extracellular Ca 2þ was attenuated in VSMCs from rats with advanced CKD. This impairment, together with reductions in expression of the Na þ / Ca 2þ exchanger, suggest a reduction in Ca 2þ extrusion capability. Finally, store-operated Ca 2þ entry (SOCE) was assessed following SR Ca 2þ store depletion. Ca 2þ entry during recovery from caffeine-induced SR Ca 2þ store release was elevated in advanced CKD, suggesting a role for exacerbated SOCE with progressing CKD. Conclusions: With progressive CKD in the Cy/þ rat there is increased resting [Ca 2þ osteogenic phenotypes, ultimately resulting in vascular calcification, a major contributor to adverse CV outcomes [9] [10] [11] [12] [13] [14] [15] [16] . However, upstream signaling events important in this contractile to osteogenic phenotypic switch have not been identified in CKD.
We recently demonstrated decreased expression of myocardin in ex vivo arterial tissue and cultured VSMCs from CKD animals compared with normal littermates [9] . Myocardin is considered the master regulator underlying the VSMC phenotypic switch from a contractile to synthetic state and is a common signaling target for many factors important in the pathogenesis of arterial diseases [17, 18] . The majority of these stimuli signal through intracellular free calcium ([Ca 2þ ] i )-mediated pathways, and altered [Ca 2þ ] i homeostasis has been found in atherosclerosis [19] [20] [21] [22] and arteriosclerosis [23] ] i are greater in several other CKD cell types, including cardiomyocytes [24, 25] , brain synaptosomes [26] , pancreatic islets [27] , polymorphonuclear leukocytes [28] [29] [30] , T-cells [31] , and platelets [32] , and suggested elevated parathyroid hormone (PTH) as a causative factor. Polak-Jonkisz et al. [33] [35] . However, changes in [Ca 2þ ] i in VSMCs have not been examined in either preclinical or in vivo models of progressive CKD. Therefore, we tested the hypothesis that there is increased [Ca 2þ ] i in VSMCs in uremia by examining changes in freshly isolated VSMCs from the male Han:SPRD Cy/þ rat [3, 36, 37] . Male Cy/þ rats develop CKD by $10 weeks of age and generally die of uremic complications by 40 weeks. As the glomerular filtration rate progressively declines, the animals develop hypertension, left ventricular hypertrophy, diastolic dysfunction and CKD-MBD (vascular medial calcification, elevated PTH, fibroblast growth factor 23 (FGF23) and phosphorus, and renal osteodystrophy) [3, 36, 37] . This model allows examination of the changes in [Ca 2þ ] i in VSMCs in response to the in vivo uremic milieu by comparing normal and CKD rats early and late in the course of CKD progression.
M A T E R I A L S A N D M E T H O D S

Animal model and experimental design
The Cy/þ rat model of progressive CKD has been previously described in detail [36] [37] [38] [39] . The genetic defect is currently under investigation but appears to result from a defect in the SamCystin gene (also known as Anks6). Recently, mutations in Anks6 were found to cause the autosomal dominant cystic phenotype in the Cy/þ rat, as well as in the autosomal recessive human cystic disease nephronophthisis [40] [41] [42] . Male Han:SPRD Cy/þ rats had access to standard grain-based protein chow and tap water through age 24 weeks and at 25 weeks changed to a casein-based protein diet (18% casein-based protein, 0.7% phosphorus, 0.7% calcium and 5% fat; Harlan Teklan TD.04539), which we have shown produces a more consistent phenotype as the disease progresses. One group of CKD rats was also supplemented with 3% calcium gluconate in the drinking water to mimic phosphate binder usage and suppress PTH. CKD rats were euthanized either at 10 weeks (early CKD, kidney function $70% of normal) or at late stages (35 weeks; advanced CKD, kidney function $15% of normal [36, 37] ). Ten and 35-week-old Han:SPRD normal rats were purchased to serve as controls. Our experimental protocol included six normal and seven CKD rats that were euthanized at 10 weeks. At 34 6 1 week of age, six normal rats, six CKD rats and eight CKD þ Ca rats were euthanized, the variable timing being due to availability of the [Ca 2þ ] i imaging system. Serum was obtained from all animals via cardiac puncture and stored at À80 C for measurement of serum biochemistries. The descending thoracic aorta was freely dissected and partitioned. The lower thoracic aorta was snap frozen at À80 C for protein or RNA isolation. The upper and middle thoracic aorta sections were used to freshly isolate VSMC. All protocols involving rats were approved by an Institutional Animal Care and Use Committee with adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals [88] .
Serum biochemistries
Plasma was analyzed for calcium, phosphorus and blood urea nitrogen (BUN) using colorimetric assays (Point Scientific, Canton, MI, USA). Intact PTH was measured by ELISA (Alpco, Salem, NH, USA) and FGF23 was assessed with a two-site assay (Immutopics, San Clemente, CA, USA) [36] [37] [38] [39] .
Protein isolation and western blotting
Protein was isolated from rat aorta by cutting aorta tissue into small pieces and placing it in 500 mL of radioImmunoprecipitation assay (RIPA) buffer and homogenizing using the Bullet Blender (Next Advance, Averill Park, NY, USA) on Speed Setting 8 for 3 min for up to five rounds according to the manufacturer's instructions. Western blotting was performed using the standard protocol. Blots were incubated with antibody against the sarco-/endoplasmic reticulum Ca 2þ ATPase 2a (SERCA2a) (1:500 dilution, antimouse antibody gifted from Indiana University School of Medicine Cardiology), Na þ /Ca 2þ exchanger 1 (NCX1) and transient receptor potential channel canonical 3, 6 and 7 (TRPC 3/6/7) (1:100, Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4 C followed by incubating with peroxidase-conjugated secondary antibody (1:5000) and immunodetection with the Enhanced Chemiluminescence Kit (Amersham, Piscataway, NJ, USA). Band intensity was analyzed using the ChemiDoc MP Imaging System (Imaging Lab 4.0, Bio-Rad, Richmond, CA, USA). Blots were stripped with ReBlot Plus Strong Antibody Stripping Solution using the standard protocol (Millipore, Billerica, MA, USA) and incubated with Beta Actin (sc-47778 at 1:1000; Santa Cruz Biotechnology, Dallas TX, USA) followed by incubation, immunodetection and measurement of band intensity. 
Total RNA was isolated from the same segments of aorta as protein using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instruction. TRPC6 expression was analyzed by real-time PCR using the TaqMan Gene Expression Assay system (Applied Biosystems) and normalized by b-actin as we previously published [9] .
Isolation of vascular smooth muscle cells
Upper thoracic aortic segments were opened longitudinally to expose the lumen and placed in a petri dish containing a lowcalcium enzymatic solution (2 mL) containing 335 U/mg type II collagenase (Worthington, Lakewood, NJ, USA), 2 mg/mL bovine serum albumin (Fraction V, Sigma Chemical, St. Louis, MO, USA), 1 mg/mL soybean trypsin inhibitor (Worthington) and 0.4 mg/mL DNase I (type IV, Sigma Chemical). Samples were placed in a shaking water bath (100 strokes/min) at 37 C for 60 min. The first fraction, containing primarily endothelial cells, was discarded. Another 2 mL of enzymatic solution was incubated in a shaking water bath for 60 min and again the supernatant was discarded. A third 2 mL enzymatic aliquot was incubated in a shaking water bath for 30 min and then centrifuged at 900 rpm for 4 min at 4 C. Supernatant was discarded and the pellet resuspended in 1 mL physiologic saline solution (PSS) þ 0.2% bovine serum albumin solution. After 2.5 h of digestion, dispersed cells contained primarily VSMCs that could be identified morphologically. Only cells with normal VSMC morphology were used to determine intracellular calcium.
All imaging was performed within 6 h of isolation. Whole cell [Ca 2þ ] i levels were obtained at room temperature using the fluorescent Ca 2þ indicator fura-2 and the ratiometric InCyt_Im2 Calcium Imaging System (Intracellular Imaging, Cincinnati, OH, USA) as previously described [43] . Freshly isolated VSMCs were incubated with 2.5 lM fura-2 AM (Molecular Probes, Eugene, OR, USA) in a shaking water bath at 37 C for 30 min followed by centrifugation at 900 rpm for 4 min at 4 C. The pellet was resuspended in physiological buffer for 20 min in the shaking water bath. An aliquot of fura-2-loaded cells was placed on a coverslip set within a constant-flow superfusion chamber (Science Instruments Shop, University of Missouri, Columbia, MO, USA) that was mounted on an inverted epifluorescence microscope (Nikon TMS-F, Melville, NY, USA), with flow maintained at 1-2 mL/min at 25 C. Cells were allowed to adhere to the coverslip prior to imaging. Fura-2 was excited by light from a 300 W xenon arc lamp passed through a computer-controlled filter wheel containing 360 6 10 and 380 6 10 nm bandpass filters. Fluorescence emission was collected at 510 nm using a monochrome charge-coupled device camera (Cohu, San Diego, CA, USA) attached to a data acquisition computer. Whole cell [Ca 2þ ] i levels were assessed with fura-2 as previously described and detailed in Figure 2A [21, [43] [44] [45] .
Cells were first perfused with PSS ( À5 M K þ -EGTA, 10 glucose; pH 7.4). VSMCs were then allowed to recover in PSS in the presence or absence of extracellular Ca 2þ . SERCA function was interrogated by examination of the undershoot of [Ca 2þ ] i in the absence of extracellular Ca 2þ below resting levels during this recovery phase, as previously described [46] . Storeoperated Ca 2þ entry (SOCE) was assessed following caffeineinduced Ca 2þ store release by analysis of the 'shoulder/plateau' of the recovery phase in the presence of caffeine.
Statistical analysis
Biochemical data are expressed as mean 6 SD whereas, per standard convention, [Ca 2þ ] i and western blot data are expressed as mean 6 SEM. For calcium imaging studies, each animal had [Ca 2þ ] i averaged across many isolated cells and differences were assessed among treatment groups. Differences among treatment groups were compared by ANOVA with Fisher's post hoc analysis using StatView (SAS Institute, Cary, NC, USA). Differences were considered significant when P < 0.05.
R E S U L T S
Assessment of CKD
Biochemical measurements taken at the time of euthanasia are consistent with our prior published findings [3, 36, 37] : 35-week CKD rats were uremic (BUN: 57 6 8 mg/dL CKD, 58 6 12 CKD þ Ca, 15 6 1 normal; P < 0.001) and had normal calcium levels ( Figure 1A ), but were hyperphosphatemic ( Figure 1B ) and had secondary hyperparathyroidism ( Figure 1C ). The administration of calcium in drinking water suppressed PTH levels ( Figure 1C ). However, as we have previously demonstrated [39] , calcium administration also increased FGF23 levels (normal ¼ 518 6 22 pg/mL, CKD ¼ 4272 6 995 and CKD þ calcium ¼ 25 035 6 8937; P < 0.05). Ten-week CKD rats were also more uremic than the normal rats (BUN ¼ 49 6 6 versus 28 6 3 mg/dL, respectively; P < 0.001), but had no biochemical manifestations of CKD-MBD.
Baseline [Ca 2þ ] i is elevated in late CKD
Using the protocol outlined in Figure 2A and detailed in the methods, a variety of Ca 2þ handling events were examined with fura-2 in early (10 weeks of age) and late (35 weeks of age) CKD. [Ca 2þ ] i was detected by exciting fura-2 alternately at 360 and 380 nm (F 360 /F 380 ); fluorescence emission was collected at 510 nm. In early CKD (10 weeks in Figure 2B ), VSMCs demonstrated decreased baseline F 360 /F 380 indicative of decreased [Ca 2þ ] i (response i in Figure 2A ) compared with age-matched normal rats (NL in Figure 2B ). However, in VSMCs from rats with late CKD (35-week in Figure 2B ), baseline levels were elevated compared with age-matched normal rats ( Figure 2B Figure 2A ). CKD had no effect on Ca 2þ entry following depolarization (F 360 /F 380 0.05 6 0.01 normal, 0.07 6 0.01 CKD, 0.05 6 0.01 CKD þ Ca; P ¼ NS, not graphed).
SR Ca 2þ store release is increased in CKD
The SR serves as an intracellular Ca 2þ reserve that is easily released with caffeine. Following Ca 2þ influx due to VGCC activity, the SR Ca 2þ store is maximally loaded. SR Ca 2þ store capacity is measured as the rise in cytosolic Ca 2þ following maximal depletion with 5 mM caffeine in the absence of extracellular Ca 2þ (response iii in Figure 2A ). SR Ca 2þ store release ( Figure 2C ) increased with CKD severity ( Figure 2C ). Ca 2þ treatment partially reversed the CKD-induced increase in SR Ca 2þ store capacity (CKD þ Ca in Figure 2C ). We therefore examined protein expression of SERCA2a at both 10 and 35 weeks. At 10 weeks of age, SERCA expression was significantly greater in CKD rats compared with normal rats (3.26 6 2.14 versus 0.69 6 0.17; P < 0.01). Surprisingly, at 35 weeks (Figure 3 ), SERCA2a expression was decreased (Figure 3 ; P < 0.01). There was no difference in SERCA2a expression between CKD and the CKD þ Ca-treated rats (Figure 3) .
Although SERCA protein expression was decreased with advanced CKD, expression does not always reflect function. Therefore SERCA buffering activity was assessed by examination of the undershoot of cytosolic Ca 2þ below baseline levels during recovery from SR Ca 2þ store depletion (response iv in Figure 2A ). VSMCs from aortas after 35 weeks of CKD displayed greater SERCA activity compared with normal samples ( Figure 2D ). Ca 2þ treatment did not alter SERCA buffering activity. Thus the increased SR Ca 2þ store capacity can be explained by increased SERCA function rather than by increased SERCA expression. (Figure 3) . Ca 2þ treatment (CKD þ Ca) further diminished NCX expression (Figure 3 ). This suggests a progressive decline in the cells ability to extrude calcium from cells with progressive uremia.
Additionally, depletion of the SR Ca 2þ store may trigger Ca 2þ entry through store-operated Ca 2þ channels located on the sarcolemma. We observed a marked attenuation in recovery of [Ca 2þ ] i to baseline levels, giving the appearance of a 'shoulder' late in the recovery phase (response v-SOCE in Figure 2A ) in the presence of physiologic levels of extracellular Ca 2þ (2Ca) compared with extracellular Ca 2þ (0Ca), which may be due to extrusion impairment or elevated SOCE. To examine whether SOCE might play a potential role in this observed attenuation of recovery, we determined whether this shoulder persists during the recovery phase following release of the SR Ca 2þ store in the absence of extracellular Ca 2þ (0Ca Figure 2E ), the recovery 'shoulder' is increased, compared with the normal phenotype. This increase was not abated with Ca 2þ treatment (CKD þ Ca; Figure 2E ). These results suggest a role for SOCE, but are not definitive. Further examination, such as manganese quench [21] , is required for verification of SOCE differences. Similar to our other results, the increase in the recovery 'shoulder' was not observed in early CKD (10 weeks of age; data not shown), suggesting a change with progression of CKD.
We then assessed expression of a major SOCE, the transient receptor potential canonical receptor TRP3/6/7 by western blot and TRPC6 by RT-PCR and found no difference in the groups (for western blot: normal ¼ 2.10 6 1.10, CKD ¼ 2.52 6 2.2, CKD þ Ca ¼ 1. 
D I S C U S S I O N
The divalent cation Ca 2þ is arguably the most important signaling molecule in cell biology. We demonstrate for the first time in freshly isolated thoracic aorta VSMCs from CKD rats that progressive CKD is a state of increased [Ca 2þ ] i . As opposed to acute injury models that induce CKD, the slowly progressive Cy/þ rat model of cystic kidney disease affords us the opportunity to examine changes over time. Early in the course of disease (at 10 weeks, $70% normal kidney function), baseline [Ca 2þ ] i was significantly lower in VSMCs from CKD rats compared with normal rats, which was accompanied by increased SERCA2a expression. Similar up-regulation of SERCA protein expression and function was shown in coronary smooth muscle of diabetic dyslipidemic swine [22, 43] . However, with advanced disease (35 weeks, $15% of normal kidney function), many Ca 2þ transporters become dysfunctional resulting in increased resting [Ca 2þ ] i in the CKD animals. Advanced (35 weeks) CKD resulted in decreased SERCA2a expression, but increased SR Ca 2þ store capacity and overall SERCA function. Decreases in SERCA2a expression have been implicated in VSMC proliferation [47] [48] [49] and could contribute to overall increases in resting [Ca 2þ ] i . However, SERCA2b is also expressed in VSMCs [45, 50] . While we did not examine SERCA2b expression, undoubtedly both SERCA2a and SERCA2b contribute to overall SERCA function in VSMCs. The observed elevations in SR Ca 2þ store capacity almost certainly are explained by the increased SERCA function. Additionally, overloading of the SR Ca 2þ store may result in SR Ca 2þ unloading events, in which Ca 2þ is released through either of these release channels on the SR membrane [51] [52] [53] . Such SR Ca 2þ unloading events may contribute to elevations in bulk cytosolic Ca 2þ both directly and indirectly through SOCE mechanisms. In particular, IP 3 R activation is known to elicit SOCE [54] [55] [56] . Indeed, the findings outlined in Figure 2 suggest a potential role for elevated VSMC SOCE in CKD that persists with Ca 2þ treatment; however, further experimentation is needed to confirm increased SOCE. Specifically, more definitive fura-2 studies of unidirectional Ca 2þ (divalent cation) influx such as those performed by Edward and et al. [21] using Mn 2þ quench are needed. We did not observe alterations in the expression of a variety of TRPC channels. This may indicate either that SOCE in this model is mediated through calcium release-activated calcium channel protein 1 (Orai1) [57] [58] [59] or that the increased SOCE is due to elevated activation of TRPC rather than to increased expression. Extrusion impairment, as evidenced by the observed decreased expression of NCX1 also contributes to elevations in resting Ca 2þ . Figure 4 provides a predictive model in which chronic elevations in SR Ca 2þ store may drive SR Ca 2þ unloading and subsequent SOCE, which, together with impaired extrusion through NCX, drive elevations in resting Ca 2þ . In VSMCs, [Ca 2þ ] i regulates vascular tone through excitation-contraction coupling and affects gene transcription through excitation-transcription coupling [60] [61] [62] [63] [64] [65] [66] . Some of these transcription factors include cAMP response element binding protein, nuclear factor of activated T lymphocytes (NFAT), and serum response factor [64, 66] . As shown in many disease states, most notable in atherosclerosis, as [Ca 2þ ] i increases with disease there is a complicated series of events that triggers the phenotype of the VSMCs to change from a quiescent contractile cell to a proliferative synthetic cell through down-regulation of genes such as a-SM actin and up-regulation of genes involved in proliferation. In contrast to other important disease states whereby [Ca 2þ ] i has been shown to modulate phenotypic plasticity, such as metabolic syndrome [56] or cardiovascular disease [67] [68] [69] [70] [71] [72] , the [Ca 2þ ] i dynamics of CKD VSMCs have yet to be elucidated. A particular strength of this study is the use of freshly isolated cells, which behave more similar to VSMCs in the intact artery than do cultured cells [61, 62] . Berra-Romani et al. [62] have shown that superior mesenteric VSMCs transform from a contractile to proliferative phenotype in cell culture. This is associated with changes in Ca Our results demonstrate that progression of CKD and the accumulated uremic toxins may lead to alteration in the regulation of [Ca 2þ ] i in VSMCs, leading to a synthetic state. In this rat model, we previously demonstrated in freshly isolated rat aorta that the expression of myocardin is decreased and angiotensin 1 receptor (AT1R) and RUNX2 are increased [9] , consistent with a proliferative state in vivo. Although elucidation of the underlying cause of altered [Ca 2þ ] i regulation is beyond the scope of this study and is almost certainly multifactorial, we did examine the possibility of PTH. Massry et al. had previously demonstrated that changes in circulating PTH in CKD rats altered [Ca 2þ ] i in other cell types [24, 25, [27] [28] [29] [30] [31] [32] . Based on these studies, we treated one group of CKD animals with calcium as a phosphate binder, which we have previously shown to suppress PTH [3, 37, 39] . Our results in the CKD animals treated with calcium to suppress PTH were difficult to interpret. SR Ca 2þ store release and NCX1 expression were lower in the CKD þ This may be due to small sample size and normal animal variability. Another possibility is that additional stimuli increase Ca 2þ entry from the extracellular space. In addition to lowering PTH, the calcium treatment also increased FGF23, as we have previously demonstrated [39] , and FGF23 has been shown to increase [Ca 2þ ] i in cardiomyocytes via the NFAT pathway [72] . Furthermore, in a klotho knock-out mouse model, Gui et al. [10] demonstrated decreased expression of NCX1 in cultured VSMCs due to high miR-135a, resulting in greater [Ca 2þ ] i that was then decreased in the presence of a miR-135a inhibitor, suggesting that klotho, which is known to be decreased in CKD, may alter our expression data [10] . It is also possible that differences in the protein source of the diet may have altered the results due to changes in CKD-MBD. Therefore, differential effects of PTH, FGF23 and klotho on [Ca 2þ ] i homeostasis in VSMCs will need to be further examined, and VSMCs may be yet another target organ in which these hormones interact.
In addition to derangements in mineral metabolism, other potential mechanisms may lead to these observations, including up-regulation of the angiotensin receptor, which we have previously identified in VSMCs from this CKD model [9] . Signaling through the angiotensin receptor induces increased [Ca 2þ ] i through phospholipase C and IP 3 , which has downstream effects on pathways including MAP kinases, receptor tyrosine kinases and non-receptor tyrosine kinases, all of which result in cellular growth, contraction, migration and hypertrophy [74] . Angiotensin receptor signaling can also activate NADPH oxidase resulting in reactive oxygen species generation in VSMCs [75] . Pathologic angiotensin receptor signaling has been found to contribute to disease in hypertension, heart failure and coronary artery disease and may play a role in [Ca 2þ ] i homeostasis of CKD VSMCs [76] . Angiotensin and other uremic toxins also increase oxidative stress. Pathologic levels of oxidative stress have been shown to be present in blood and aorta tissue in animal models and humans with CKD and are associated with coronary artery calcification [77] [78] [79] . Oxidative stress up-regulates RUNX2, necessary for the vascular phenotype that promotes calcification [80, 81] . Oxidative stress and [Ca 2þ ] i signaling are clearly linked [82] . Agonist-induced increases in [Ca 2þ ] i increase reactive oxygen species production through enzymes such as NADPH oxidases. The increase in oxidative stress ultimately causes post-translational modifications of common Ca 2þ proteins, such as VGCC, RyR, SERCA and TRPC, thus changing [Ca 2þ ] i [82] [83] [84] [85] [86] [87] . Our CKD animals have increased RNA expression of NADPH oxidase 4 in aorta tissue (1.1 6 0.2 normal versus 1.6 6 0.2 CKD, normalized to b-actin, P < 0.05; unpublished data). Future studies in our CKD rat model to determine if lowering PTH, FGF23 and/or oxidative stress impacts VSMC [Ca 2þ ] i homeostasis will be important. In summary, we provide evidence for pathologically increased VSMC resting [Ca 2þ ] i and increased SR Ca 2þ store with progressive CKD in our rat model. Resting [Ca 2þ ] i increases as the kidney disease progresses, in part due to decreased protein levels of NCX1, implying inadequate Ca 2þ extrusion, together with increased SOCE. Importantly, these observations were in freshly isolated VSMCs and thus do not represent a cell culture artifact, a common issue in many studies. However, which uremic toxin, or more likely multiple toxins, leads to these changes, and how MBD treatments modulate these changes, will require further study. 
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